Plain-English translation of NCT07554521 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new immunotherapy drug called combined with standard chemotherapy for advanced stomach and esophageal cancers that cannot be surgically removed. The medication is designed to help your immune system fight cancer cells more effectively. Researchers want to see if this combination works well and is safe, especially for patients from Black, Hispanic, Native American, and Pacific Islander communities.
Advanced stomach and esophageal cancers are serious diseases with limited treatment options. This medication works differently than traditional chemotherapy alone, and researchers believe combining it with chemotherapy may help more patients survive longer and live better lives.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication and chemotherapy together over the course of the study, with treatment visits occurring every 2 or 3 weeks depending on which chemotherapy regimen you receive. The medication and chemotherapy can be given intravenously (through an IV) or as pills, depending on the specific regimen your doctor chooses. The study lasts up to approximately 6 years and involves regular doctor visits, blood tests, imaging scans, and safety monitoring to see how well the treatment is working and how your body is tolerating it.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States